Shares of Syneron Medical Ltd. (Nasdaq:ELOS) are getting a pop before the opening bell after the developer of elos combined-energy medical aesthetic devices reported first-quarter earnings this morning that trumped the consensus on Wall Street. Revenues edged up 5% in the quarter, as the company reaped the benefits of a more diversified business model, but fell below analysts’ mean estimate.

Shares gained 8%, or $1.25, to $16.48 in pre-market trading. For detailed price information and recent news stories about Syneron Medical, click ELOS.